ScanSource's Bargain Already Left. What's Left Is a Bet on a Pivot

A stock that jumped 27% in a single morning sounds like the last thing a bargain hunter would chase, but that is precisely the pitch floating around ScanSource (NASDAQ: SCSC) since August 20. The Greenville, South Carolina technology distributor — barcode scanners, POS terminals, networking gear, physical security — had just reported a fiscal Q4 anyone would want: net sales up 17.3% to $953.1 million and record non-GAAP EPS of $1.46, blowing past the consensus estimate of $1.14 and a revenue call of roughly $814 million. The shares, already up sharply for the year from a 52-week low near $34, spiked to $65-plus before settling back near $57.

The interesting question is not whether last quarter was good. It is whether, with the stock up about 47% year to date, the bargain that the "fast-paced mover" framing advertises is still actually there. The honest answer: the deep discount left with the old price. What remains is a fair-value cyclical recovery whose entire upside now hinges on whether ScanSource can earn the higher multiple the market has already handed it.

Why this stock was ever cheap

Distribution is one of those businesses that looks fine in the income statement and ugly in the margins. ScanSource keeps roughly 14 cents of every sales dollar as gross profit and only about 3 cents of operating profit out the bottom. When you operate on that kind of cushion, years get lumpy: within the record fiscal 2026, quarterly EPS swung from $0.80 in the December quarter to the $1.46 record in June — a low-margin model where revenue timing shifts per-share results dramatically.

That sensitivity is exactly what made the stock cheap, and it explains the arc. In fiscal 2025, ScanSource's sales fell 6.7% to $3.04 billion, with one quarter down 15.5% year over year, as management described a cautious technology spending environment in the first half. The market decided the company was a value trap — a distributor in structural decline — and marked the shares down near $34. That is roughly 8x the record $4.24 per share it would go on to earn a year later. The bargain-lover's story was born from that pessimism.

Here is what that story got wrong: even through the down year, earnings kept rising. Non-GAAP EPS grew about 16% in fiscal 2025 to $3.57, and then 19% in fiscal 2026 to the record $4.24 on a 6.1% rise in sales. The market priced an earnings collapse that never arrived; the pessimism was overdone, and the second-half recovery in demand — larger deals, physical security, broad-based hardware — carried Q4 over the finish line.

What changed: it is no longer just a box seller

Part of the re-rating is deserved, because the business mix is measurably different from the pure distribution model that earns single-digit multiples. Recurring revenue — SaaS, cloud, managed services — grew 10.6% in fiscal 2026 and is now about a third of gross profit, up from 32.8% last year. The small Intelisys & Advisory segment runs adjusted EBITDA margins near 36%, roughly eight times the companywide 4.7%, and it is growing.

Then, on the same day as the earnings blowout, management announced its biggest pivot yet: a definitive agreement to buy MicroAge, an IT solutions integrator with about 2,400 U.S. clients, for $220.5 million in cash. MicroAge brings cloud, cybersecurity, data center, and AI capabilities plus managed services — the higher-margin areas of the channel where a pure reseller cannot reach. The deal is expected to close by September 30 and to be accretive to gross margin, adjusted EBITDA margin, and non-GAAP EPS in its first year. Distribution is a multiple-killing business; services and recurring revenue are multiple-friendly. MicroAge is the clearest statement yet that ScanSource is trying to make the conversion.

The part that kills the "bargain" claim

Now the counterweight, because the company's own numbers put a ceiling on how cheap this can honestly be called. ScanSource's fiscal 2027 outlook — explicitly before any MicroAge contribution — calls for organic sales growth of 6% to 10%, adjusted EBITDA of $158 million to $165 million, and free cash flow of at least $85 million.

Read that cash-flow line twice, because it is the tell. Fiscal 2026 produced $113.8 million in free cash flow. A "floor" of $85 million for the year ahead is the company itself signaling that cash generation steps down — working capital needed to fund growth, most likely — from the level that made the stock look like a 10% free-cash-flow yield at $57. On the guidance floor, that yield is closer to 7%. Decent, but not the discount the trailing numbers advertise. Add in the street's forward estimates, which now embed the MicroAge financing and integration costs against a decelerating organic growth path, and data services put ScanSource's forward P/E near 16x — above its trailing multiple, not below it. Management also flagged that the first half of fiscal 2027 will grow faster than the second, because comparisons get harder.

The peer check finishes the argument. On the measure that best compares distribution businesses, trailing EV/EBITDA, the two larger distributors TD SYNNEX and Arrow Electronics trade around 10.9x and 9.4x; ScanSource, after the run, sits near 11.8x. On forward and peer bases, ScanSource is no longer the discount name in the group. The cheap is done.

What you are actually buying now

None of this makes ScanSource a bad business, and I am not calling a top. The trade has simply changed character. At $34, the setup was clean: an overdone selloff with intact fundamentals and an 8x multiple — the textbook contrarian entry. At $57, no one is paying you to tolerate an ugly chart. You are paying a fair price for a cyclical recovery and betting on the harder thing: that the services pivot and the MicroAge integration actually lift margins and cash flow rather than just resize the mix.

So name the conditions. MicroAge closes by the end of September and the updated guidance including it demonstrates the promised accretion. Recurring revenue's share of gross profit keeps climbing. And free cash flow lands above the $85 million floor rather than limping toward it. Any of those fails, and the re-rating has once again gotten ahead of the numbers — which is exactly how a "fast mover" gives the move back.

The one downgrade that preceded earnings — Northcoast Research cutting SCSC to Hold near $59 after the rally — was a price-based call, not a thesis-based one, which is usually positioning noise rather than information. And the technical picture is consistent: after the spike, shares pulled back from the post-earnings high near $67 toward $57, still above their 50- and 200-day averages with RSI near 58. An uptrend that has cooled, not a collapse. Chasing at $65 was the mistake; waiting for the harder evidence is not waiting for a falling price, it is waiting for facts.

AInvest's aggregate signal currently labels the stock a Hold, and on the evidence I cannot call that a lazy consensus — it is close to what a disciplined valuation says here. The bargain-hunter framing worked at $34; at $57 it is a stale poster. If you want to own the pivot, you buy it after the third quarter proves it in the numbers, not before. If you already own the recovery, the re-rating has done much of its work, and the fade from $67 to $57 is a reminder that one-day pops can give some back. The market is no longer clearly wrong about ScanSource. For a bargain hunter, that used to be the entire pitch — and it is gone.